Aug 04, 2022
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
Jul 27, 2022
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
Jul 25, 2022
Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184
Jun 22, 2022
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022
Jun 06, 2022
Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential
May 23, 2022
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
May 04, 2022
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
May 03, 2022
Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022
Apr 27, 2022
Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
Apr 04, 2022
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
Displaying 1 - 10 of 17